Logo Image
Opinion|Videos|October 21, 2024

Factors Impacting Use of HER2 Therapies for NSCLC

Key Takeaways

  • Barriers to HER2-directed therapies include high costs, limited insurance coverage, and stringent prior authorization requirements, impacting patient access and treatment initiation.
  • Providers prioritize clinical outcomes like progression-free survival and overall response rates, which may not align with payer focus on cost-effectiveness.
SHOW MORE

Panelists discuss how payer perspectives and access challenges impact the utilization of HER2-directed therapies in NSCLC, examining barriers to treatment initiation and persistence, aligning provider and payer priorities in outcome assessment, the role of real-world evidence in decision-making and policy formation, and strategies for collaborative efforts between stakeholders to balance equitable access with cost management.

Episodes in this series

Video content above is prompted by the following:

Analyze payer perspectives and access challenges related to HER2-directed therapies in NSCLC.

  • (Kim) What are potential barriers to starting and/or persisting on HER2-directed therapies for NSCLC?
  • (Bazhenova) Which outcomes do providers find most important in clinical practice, and how do these align with the outcomes payers prioritize when assessing the value of these therapies?

Related Content